1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A

2.60
USD
-0.07
(-2.62%)
4.91BMarket Cap
Oct 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.55
4.11
4.07
3.51
3.21
3.58
3.92
3.71
3.89
4.64
4.61
4.11
2.77
- -
Basic EPS, GAAP
0.21
0.21
0.26
0.24
0.27
0.32
0.35
0.37
0.43
0.48
0.55
1.25
1.2
- -
Free Cash Flow per Basic Share
0.08
0.13
0.15
0.17
-0.07
0.1
0.16
0.27
0.39
0.32
0.31
0.45
0.19
- -
Dividend per Share
0.09
0.07
0.08
0.12
0.07
0.09
0.1
0.13
0.13
0.22
0.49
0.57
0.55
1.84
Book Value per Share
1.41
1.62
2.21
2.35
2.54
2.77
3.03
3.25
3.56
3.65
3.71
4.41
3.99
3.34
Tangible Book Value per Share
1.3
1.5
2.1
2.25
2.44
2.67
2.93
3.13
3.45
3.44
3.48
4.21
3.81
3.17
Basic Weighted Avg Shares
1,694
1,723
1,739
1,780
1,775
1,779
1,785
1,779
1,778
1,779
1,782
1,777
1,778
1,023
Sales/Revenue/Turnover
6,010
7,087
7,081
6,243
5,689
6,359
6,994
6,604
6,908
8,249
8,222
7,307
4,917
- -
Operating Margin (%)
5.65
5.46
6.1
5.07
6.28
7.49
8.09
9.02
8.88
8.77
10.56
11.7
19.75
- -
Depreciation Expense
83
84
70
70
73
76
98
111
116
117
130
126
116
- -
Net Income, GAAP
352
358
451
424
476
562
626
662
769
862
987
2,229
2,131
- -
Effective Tax Rate (%)
13.54
11.94
14.76
12.36
10.87
11.37
14.5
11.51
9.85
10.91
11.56
14.1
15.14
- -
Profit Margin (%)
5.85
5.05
6.38
6.79
8.37
8.83
8.94
10.02
11.13
10.45
12
30.51
43.34
- -
Working Capital
635
1,020
2,158
1,985
2,108
2,865
2,978
3,440
3,991
3,912
3,319
3,790
2,648
1,718
LT Debt
4
4
4
4
39
4
33
32
2
152
244
6
5
5
Total Equity
2,575
2,947
4,105
4,345
4,666
5,054
5,523
5,950
6,514
6,552
6,645
7,850
7,100
5,940
Return on Invested Capital (%)
10.63
10.18
10.57
8.51
9.96
11.23
12.03
12.18
12.67
13.13
14.05
29.25
27.63
- -
Return on Capital (%)
11.42
10.26
11.44
9.87
10.13
11.01
11.41
11.16
12.04
12.87
15.04
30.67
28.7
- -
Return on Common Equity (%)
15.45
13.81
13.51
10.45
10.94
11.89
12.13
11.82
12.64
13.38
15.04
30.87
28.52
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
61
52
84
LT Borrowings
- -
- -
- -
LT Finance Leases
5
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,780
1,780
1,780
Market Capitalization
42,447
39,659
33,334

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
7,155
6,116
6,229
Cash, Cash Equivalents & STI
1,016
902
2,448
Accounts Receivable, Net
973
1,279
776
Inventories
1,133
1,078
1,111
Total Current Liabilities
4,506
2,829
4,510
Payables & Accruals
- -
- -
- -
ST Debt
61
52
84
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.86%
4.01%
-9.55%
Free Cash Flow
-23.03%
2.41%
-57.56%
Net Income, GAAP
20.57%
32.86%
-4.41%
Sales/Revenue/Turnover
-2.47%
-4.03%
-32.7%
Total Cash Common Dividend
27.89%
41.09%
-2.9%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,086
1,879
1,646
1,696
7,307
2025
1,455
1,195
- -
1,247
4,917
2026
1,515
939
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.35
0.19
1.85
1.25
2025
0.21
2.02
- -
-0.03
1.2
2026
0.24
0.29
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
1.26
0.04
0.57
2025
- -
- -
- -
- -
0.55
2026
1.05
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hong Chen
Full Time Employees
3,890
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 17, Baidi Road Tianjin TI China 300193
IPO Date
Jun 6, 2001
Website
en.jydrt.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS), controlled by Tianjin Pharmaceutical Holdings Co., Ltd., manufactures and sells traditional Chinese medicines, western medicines, and healthcare products primarily in China with expanding international presence in Asia, Europe, and the United States; core offerings span 22 dosage forms and 599 drug approvals, including proprietary brands such as Suxiao Jiuxin Pills (national confidential dripping pills for cardiovascular conditions), Jingwanhong Ointment (national secret ointment for skin wound repair), Yinqiao Jiedu Tablets, Huoxiang Zhengqi Tincture, Niuhuang Qingxin Pills, Qinggong Shoutao Pills, quick-acting heart saving pills under the China Heart series, Beijing Wanhong Ointment under the China Skin series, and China Brain series products; additional segments cover chemical raw materials, preparations, nutritional health products, drug retail, respiratory drugs, digestion drugs, and rheumatism treatments. Founded with roots tracing to 1669 and formally established in 1981, the company, headquartered at 17 Baidi Road, Nankai District, Tianjin, China, operates as a national high-tech enterprise pioneering modern TCM preparation technology, including the first GMP-certified TCM factory, and holds four China Time-Honored Brands (Da Ren Tang, Le Ren Tang, Ching Wan Hung, Long Shun Rong), five national intangible cultural heritage projects, and six well-known trademarks. In May 2022, the company renamed from Tianjin Zhongxin Pharmaceutical Group Corporation Limited to its current name, aligning with the 14th Five-Year Plan's "1+5" strategy focused on three core areas—cardiovascular and cerebrovascular drugs, skin wound repair drugs, high-quality TCM healthcare—and nine supporting lines; it renewed connected transaction agreements with Tianjin Pharmaceutical Group in November 2024 for chemical drugs and products effective January 2025; and in April 2025, agreed to sell its remaining 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd joint venture to Haleon plc for CNY 1.62 billion, completing Haleon's full ownership.